올리고뉴클레오티드 합성 시장 규모, 점유율 및 동향 분석 보고서 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문 예측(2026-2033년)

Oligonucleotide Synthesis Market Summary

The global oligonucleotide synthesis market size was estimated at USD 3.64 billion in 2025 and is projected to reach USD 10.86 billion by 2033, growing at a CAGR of 14.95% from 2026 to 2033. Growth is driven by increasing use of oligonucleotides in therapeutics and diagnostics, rising genomics research investments, and technological advances in scalable synthesis, with strong demand from pharmaceutical and biotechnology companies supporting market expansion.

Growth of Nucleic Acid-Based Therapies

The primary factor responsible for the growth of the oligonucleotide synthesis market is the rapidly growing nucleic acid-based therapies. High-precision oligonucleotides are needed for therapeutic measures like antisense oligonucleotides, siRNA, mRNA therapies, and gene-editing technologies, which, in turn, require more accurate and more extensive synthesis. Moreover, the increasing number of regulatory approvals and the ongoing strong clinical pipeline against genetic, oncological, and infectious diseases are also contributing to the growth of the market.

Global Oligonucleotide Synthesis Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global oligonucleotide synthesis market on the basis of product & service, application, end-use, and region:

• Product & Service Scope Outlook (Revenue, USD Million, 2021 - 2033)
• Oligonucleotides
  • Product type
  • DNA
  • Technology
  • Column-based
  • Array-based
  • RNA
  • Technology
  • Column-based
  • Array-based
  • Type
  • Short RNA Oligos (<65 nt)
  • Long RNA Oligos (>65 nt)
  • CRISPR (sgRNA)
• Equipment/Synthesizer
• Reagents
• Services
  • DNA
  • Custom Oligo Synthesis Services
  • 25 nmol
  • 50 nmol
  • 200 nmol
  • 1000 nmol
  • 10000 nmol
  • Modification Services
  • Purification Services
  • RNA
  • Custom Oligo Synthesis Services
  • 25 nmol
  • 100 nmol
  • 1000 nmol
  • 10000 nmol
  • Modification Services
  • Purification Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• PCR Primers
• PCR Assays and Panels
• Sequencing
• DNA Microarrays
• Fluorescence In Situ Hybridization (FISH)
• Antisense Oligonucleotides
• Other Applications
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic Research Institutes
• Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Regional Outlook (Revenue, USD Million, 2021- 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product & Service Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective2
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growth of nucleic acid-based therapies
    • 3.2.1.2. Rising use in molecular diagnostics
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost associated with genomics research
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Product & Service Business Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Oligonucleotide Synthesis Market: Product & Service Movement Analysis
• 4.3. Oligonucleotides
  • 4.3.1. Global oligonucleotides market, 2021 - 2033 (USD million)
  • 4.3.2. Product type
    • 4.3.2.1. Global product type oligonucleotides market, 2021 - 2033 (USD million)
    • 4.3.2.2. DNA
      • 4.3.2.2.1. Global DNA market, 2021 - 2033 (USD million)
      • 4.3.2.2.2. Technology
        • 4.3.2.2.2.1. Global technology oligonucleotides market, 2021 - 2033 (USD million)
        • 4.3.2.2.2.2. Column-based
          • 4.3.2.2.2.2.1. Global column-based market, 2021 - 2033 (USD million)
        • 4.3.2.2.2.3. Array-based
          • 4.3.2.2.2.3.1. Global array-based market, 2021 - 2033 (USD million)
    • 4.3.2.3. RNA
      • 4.3.2.3.1. Global RNA market, 2021 - 2033 (USD million)
      • 4.3.2.3.2. Technology
        • 4.3.2.3.2.1. Global technology oligonucleotides market, 2021 - 2033 (USD million)
        • 4.3.2.3.2.2. Column-based
          • 4.3.2.3.2.2.1. Global column-based market, 2021 - 2033 (USD million)
        • 4.3.2.3.2.3. Array-based
          • 4.3.2.3.2.3.1. Global array-based market, 2021 - 2033 (USD million)
      • 4.3.2.3.3. Type
        • 4.3.2.3.3.1. Global type oligonucleotides market, 2021 - 2033 (USD million)
        • 4.3.2.3.3.2. Short RNA Oligos (<65 nt)
          • 4.3.2.3.3.2.1. Global short RNA oligos (<65 nt) market, 2021 - 2033 (USD million)
        • 4.3.2.3.3.3. Long RNA Oligos (>65 nt)
          • 4.3.2.3.3.3.1. Global long RNA oligos (>65 nt) market, 2021 - 2033 (USD million)
        • 4.3.2.3.3.4. CRISPR (sgRNA)
          • 4.3.2.3.3.4.1. Global CRISPR (sgRNA) market, 2021 - 2033 (USD million)
• 4.4. Equipment/Synthesizer
  • 4.4.1. Global equipment/synthesizer market, 2021 - 2033 (USD million)
• 4.5. Reagents
  • 4.5.1. Global reagents market, 2021 - 2033 (USD million)
• 4.6. Services
  • 4.6.1. Global Services market, 2021 - 2033 (USD million)
  • 4.6.2. DNA
    • 4.6.2.1. Global DNA market, 2021 - 2033 (USD million) market, 2021 - 2033 (USD million)
    • 4.6.2.2. Custom Oligo Synthesis Services
      • 4.6.2.2.1. Global custom oligo synthesis services market, 2021 - 2033 (USD million)
      • 4.6.2.2.2. 25 nmol
        • 4.6.2.2.2.1. Global 25 nmol market, 2021 - 2033 (USD million)
      • 4.6.2.2.3. 50 nmol
        • 4.6.2.2.3.1. Global 50 nmol market, 2021 - 2033 (USD million)
      • 4.6.2.2.4. 200 nmol
        • 4.6.2.2.4.1. Global 200 nmol market, 2021 - 2033 (USD million)
      • 4.6.2.2.5. 1000 nmol
        • 4.6.2.2.5.1. Global 1000 nmol market, 2021 - 2033 (USD million)
      • 4.6.2.2.6. 10000 nmol
        • 4.6.2.2.6.1. Global 10000 nmol market, 2021 - 2033 (USD million)
    • 4.6.2.3. Modification Services
      • 4.6.2.3.1. Global modification services market, 2021 - 2033 (USD million)
    • 4.6.2.4. Purification Services
      • 4.6.2.4.1. Global purification services market, 2021 - 2033 (USD million)
  • 4.6.3. RNA
    • 4.6.3.1. Global RNA market, 2021 - 2033 (USD million)
    • 4.6.3.2. Global DNA market, 2021 - 2033 (USD million) market, 2021 - 2033 (USD million)
    • 4.6.3.3. Custom Oligo Synthesis Services
      • 4.6.3.3.1. Global custom oligo synthesis services market, 2021 - 2033 (USD million)
      • 4.6.3.3.2. 25 nmol
        • 4.6.3.3.2.1. Global 25 nmol market, 2021 - 2033 (USD million)
      • 4.6.3.3.3. 50 nmol
        • 4.6.3.3.3.1. Global 50 nmol market, 2021 - 2033 (USD million)
      • 4.6.3.3.4. 200 nmol
        • 4.6.3.3.4.1. Global 200 nmol market, 2021 - 2033 (USD million)
      • 4.6.3.3.5. 1000 nmol
        • 4.6.3.3.5.1. Global 1000 nmol market, 2021 - 2033 (USD million)
      • 4.6.3.3.6. 10000 nmol
        • 4.6.3.3.6.1. Global 10000 nmol market, 2021 - 2033 (USD million)
    • 4.6.3.4. Modification Services
      • 4.6.3.4.1. Global modification services market, 2021 - 2033 (USD million)
    • 4.6.3.5. Purification Services
      • 4.6.3.5.1. Global purification services market, 2021 - 2033 (USD million)

Chapter 5. Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Oligonucleotide Synthesis Market: Application Movement Analysis
• 5.3. PCR Primers
  • 5.3.1. Global PCR primers market, 2021 - 2033 (USD million)
• 5.4. PCR Assays and Panels
  • 5.4.1. Global PCR assays and panels market, 2021 - 2033 (USD million)
• 5.5. Sequencing
  • 5.5.1. Global sequencing market, 2021 - 2033 (USD million)
• 5.6. DNA Microarrays
  • 5.6.1. Global DNA microarrays market, 2021 - 2033 (USD million)
• 5.7. Fluorescence In Situ Hybridization (FISH)
  • 5.7.1. Global Fluorescence In Situ Hybridization (FISH) market, 2021 - 2033 (USD million)
• 5.8. Antisense Oligonucleotides
  • 5.8.1. Global antisense oligonucleotides market, 2021 - 2033 (USD million)
• 5.9. Other Applications
  • 5.9.1. Global other applications market, 2021 - 2033 (USD million)

Chapter 6. End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Oligonucleotide Synthesis Market: End Use Movement Analysis
• 6.3. Academic Research Institutes
  • 6.3.1. Global academic research institutes market, 2021 - 2033 (USD million)
• 6.4. Diagnostic Laboratories
  • 6.4.1. Global diagnostic laboratories market, 2021 - 2033 (USD million)
• 6.5. Pharmaceutical and Biotechnology Companies
  • 6.5.1. Global pharmaceutical and biotechnology companies market, 2021 - 2033 (USD million)

Chapter 7. Regional Business Analysis

• 7.1. Oligonucleotide Synthesis Market Share By Region, 2025 & 2033
• 7.2. North America
  • 7.2.1. North America Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Competitive Scenario
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. U.S. Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Competitive Scenario
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Canada Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Competitive Scenario
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Mexico Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. UK Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Germany Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. France Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Competitive Scenario
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Italy Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Competitive Scenario
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Spain Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Competitive Scenario
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Denmark Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Competitive Scenario
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Sweden Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Competitive Scenario
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Norway Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Japan Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. China Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. India Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.4.5. Australia
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Australia Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.4.6. Thailand
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Thailand Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.4.7. South Korea
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. South Korea Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Brazil Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Argentina Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. South Africa Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Saudi Arabia Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. UAE Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Kuwait Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Danaher
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Revvity Discovery Limited
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Agilent Technologies, Inc.
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Bio-Synthesis, Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Product Benchmarking
    • 8.4.6.3. Strategic Initiatives
  • 8.4.7. Kaneka Eurogentec S.A.
    • 8.4.7.1. Overview
    • 8.4.7.2. Product Benchmarking
    • 8.4.7.3. Strategic Initiatives
  • 8.4.8. LGC Biosearch Technologies
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Biolegio
    • 8.4.9.1. Overview
    • 8.4.9.2. Product Benchmarking
    • 8.4.9.3. Strategic Initiatives
  • 8.4.10. Twist Bioscience
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives